Cancer Causes & Control

, Volume 20, Issue 8, pp 1309–1316 | Cite as

Association of metabolic syndrome with insulin-like growth factors among adults in the US

  • Sharon Saydah
  • Rachel Ballard-Barbash
  • Nancy Potischman
Original paper



To examine the association of insulin-like growth factors (IGFs) with metabolic syndrome in a nationally representative sample.


We used data from the Third National Health and Nutrition Examination Survey. Analysis is based on participants who provided a fasting blood sample and were aged 20 years and older (n = 5,903). Participants were classified by a number of risk factors for metabolic syndrome and stratified by diabetes status.


Each of the components of metabolic syndrome (increased waist circumference, higher triglycerides, lower HDL cholesterol, higher blood pressure, higher fasting glucose and diabetes) was each associated with lower levels of IGF-I, IGF-BP3 and the Ratio IGF-I/IGF-BP3. Each of the metabolic syndrome components was also associated with higher levels of insulin. Participants with 3–5 components of metabolic syndrome had significantly lower IGF-I and higher IGF-BP3 levels compared to adults with 1–2 components or 0 components, after adjustment for potential confounders. Participants with diabetes had lower levels of IGF-I and IGF-BP3, and higher levels of insulin, regardless of the number of metabolic syndrome components.


These findings may prove useful to an understanding of the role of IGF-I in human disease, in particular its relation to metabolic syndrome, diabetes and potentially some cancers.


Insulin-like growth factors Metabolic syndrome NHANES 



The views and interpretations presented in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.


  1. 1.
    LeRoith D, Clemmons D, Nissley P et al (1992) NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med 116(10):854–862PubMedGoogle Scholar
  2. 2.
    Juul A (2003) Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13(4):113–170. doi: 10.1016/S1096-6374(03)00038-8 PubMedCrossRefGoogle Scholar
  3. 3.
    Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505–518. doi: 10.1038/nrc1387 PubMedCrossRefGoogle Scholar
  4. 4.
    Renehan AG, Zwahlen M, Minder C et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353. doi: 10.1016/S0140-6736(04)16044-3 PubMedCrossRefGoogle Scholar
  5. 5.
    Goodman-Gruen D, Barrett-Connor E, Rosen C (2000) IGF-1 and ischemic heart disease in older people. J Am Geriatr Soc 48(7):860–861PubMedGoogle Scholar
  6. 6.
    Janssen JA, Stolk RP, Pols HA et al (1998) Serum free and total insulin-like growth factor-I, insulin-like growth factor binding protein-1 and insulin-like growth factor binding protein-3 levels in healthy elderly individuals. Relation to self-reported quality of health and disability. Gerontology 44(5):277–280. doi: 10.1159/000022026 PubMedCrossRefGoogle Scholar
  7. 7.
    Juul A, Scheike T, Davidsen M et al (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106(8):939–944. doi: 10.1161/01.CIR.0000027563.44593.CC PubMedCrossRefGoogle Scholar
  8. 8.
    Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285(19):2486–2497. doi: 10.1001/jama.285.19.2486 CrossRefGoogle Scholar
  9. 9.
    Galassi A, Reynolds K, He J (2006) Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119(10):812–819. doi: 10.1016/j.amjmed.2006.02.031 PubMedCrossRefGoogle Scholar
  10. 10.
    Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595–1607. doi: 10.2337/diabetes.37.12.1595 PubMedCrossRefGoogle Scholar
  11. 11.
    Ahmed RL, Schmitz KH, Anderson KE et al (2006) The metabolic syndrome and risk of incident colorectal cancer. Cancer 107(1):28–36. doi: 10.1002/cncr.21950 PubMedCrossRefGoogle Scholar
  12. 12.
    Bowers K, Albanes D, Limburg P et al (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164(7):652–664. doi: 10.1093/aje/kwj253 PubMedCrossRefGoogle Scholar
  13. 13.
    Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13(2):279–292. doi: 10.1677/erc.1.00729 PubMedCrossRefGoogle Scholar
  14. 14.
    Lund HL, Wisloff TF, Holme I et al (2006) Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164(8):769–774. doi: 10.1093/aje/kwj284 CrossRefGoogle Scholar
  15. 15.
    Tande AJ, Platz EA, Folsom AR. (2006) The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164(11):1094–1102PubMedCrossRefGoogle Scholar
  16. 16.
    Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169(5):1505–1522. doi: 10.2353/ajpath.2006.051090 PubMedCrossRefGoogle Scholar
  17. 17.
    Froesch ER, Hussain MA, Schmid C et al (1996) Insulin-like growth factor I: physiology, metabolic effects and clinical uses. Diabetes Metab Rev 12(3):195–215. doi: 10.1002/(SICI)1099-0895(199610)12:3<195::AID-DMR164>3.0.CO;2-G PubMedCrossRefGoogle Scholar
  18. 18.
    Sjogren K, Wallenius K, Liu JL et al (2005) (2001) Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 50(7):1539–1545. doi: 10.2337/diabetes.50.7.1539 CrossRefGoogle Scholar
  19. 19.
    Sesti G, Sciacqua A, Cardellini M et al (2005) Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28(1):120–125. doi: 10.2337/diacare.28.1.120 PubMedCrossRefGoogle Scholar
  20. 20.
    Heald AH, Cruickshank JK, Riste LK et al (2001) Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44(3):333–339. doi: 10.1007/s001250051623 PubMedCrossRefGoogle Scholar
  21. 21.
    Gram IT, Norat T, Rinaldi S et al (2006) Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes (Lond) 30(11):1623–1631. doi: 10.1038/sj.ijo.0803324 CrossRefGoogle Scholar
  22. 22.
    Sandhu MS, Heald AH, Gibson JM et al (2002) Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359(9319):1740–1745. doi: 10.1016/S0140-6736(02)08655-5 PubMedCrossRefGoogle Scholar
  23. 23.
    Efstratiadis G, Tsiaousis G, Athyros VG et al (2006) Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 57(3):303–311. doi: 10.1177/000331970605700306 PubMedCrossRefGoogle Scholar
  24. 24.
    Maccario M, Ramunni J, Oleandri SE et al (1999) Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord 23(6):612–618. doi: 10.1038/sj.ijo.0800889 PubMedCrossRefGoogle Scholar
  25. 25.
    Sierra-Johnson J, Romero-Corral A, Sommers VK, Lopez-Jimenez F et al (2009) IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci 116:507–512. doi: 10.1042/CS20080382 PubMedCrossRefGoogle Scholar
  26. 26.
    Berrigan D, Potischman N, Dodd K et al (2009) Race/ethnic variation of serum levels of insulin-like growth factor 1 (IGF-I) and IGF-binding protein 3 (IGF-BP3) in US adults. Growth Horm IGF Res 19(2):146–155. doi: 10.1016/j.ghir.2008.08.005 PubMedCrossRefGoogle Scholar
  27. 27.
    Goodman-Gruen D, Barrett-Connor E (1997) Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo study. Am J Epidemiol 145(11):970–976PubMedGoogle Scholar
  28. 28.
    Plan and operation of the Third National Health and Nutrition Examination Survey 1988–1994 (1994) National center for health statistics. Vital Health Stat 1(32)Google Scholar
  29. 29.
    Analytic and Reporting Guideline: the third national health and nutrition examination survey, NHANES III 1988–1994 (1996) National center for health statistics, centers for disease control and prevention, Hyattsville, MarylandGoogle Scholar
  30. 30.
    Berrigan D, Potischman N, Dodd K et al (2007) Serum levels of insulin-like growth factor 1 (IGF-I) and IGF-binding protein 3 (IGF-BP3); quality control for studies of stored serum. Cancer Epidemiol Biomarkers Prev 16(5):1017–1022. doi: 10.1158/1055-9965.EPI-07-0044 PubMedCrossRefGoogle Scholar
  31. 31.
    Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. doi: 10.1007/BF00280883 PubMedCrossRefGoogle Scholar
  32. 32.
    Research Triangle Institute. SUDAAN (2004) Release 9.0. Research Triangle Institute, Research Triangle Park, NCGoogle Scholar
  33. 33.
    Calle EE, Kaaks R (2004) Overweight, obesity and cancer epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591. doi: 10.1038/nrc1408 PubMedCrossRefGoogle Scholar
  34. 34.
    Kaaks R (2004) Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp 262:247–260. doi: 10.1002/0470869976.ch16 PubMedCrossRefGoogle Scholar
  35. 35.
    Zhou JR, Blackburn GL, Walker WA (2007) Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr 86:817S–819SGoogle Scholar
  36. 36.
    Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of current evidence. Am J Clin Nutr 86:823S–835SGoogle Scholar
  37. 37.
    Hsing AW, Sakoda LC, Chua SC (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86:843S–857SGoogle Scholar
  38. 38.
    Giovannnucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:836S–842SGoogle Scholar
  39. 39.
    Pollack MN (2007) Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86:820S–822SGoogle Scholar
  40. 40.
    Dunger DB, Acerini CL (1997) Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes? Diabet Med 14(9):723–731. doi: 10.1002/(SICI)1096-9136(199709)14:9<723::AID-DIA480>3.0.CO;2-S PubMedCrossRefGoogle Scholar
  41. 41.
    Murphy LJ (2006) Insulin-like growth factor-I: a treatment for type 2 diabetes revisited. Endocrinology 147(6):2616–2618. doi: 10.1210/en.2006-0343 PubMedCrossRefGoogle Scholar
  42. 42.
    Pennisi P, Gavrilova O, Setser-Portas J et al (2006) Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147(6):2619–2630. doi: 10.1210/en.2005-1556 PubMedCrossRefGoogle Scholar
  43. 43.
    LeRoith D, Werner H, Burguera B et al (1992) The insulin-like growth factor family of peptides, binding proteins and receptors: their potential role in tissue regeneration. Adv Exp Med Biol 321:21–28PubMedGoogle Scholar
  44. 44.
    Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 28:2289–2304. doi: 10.2337/diacare.28.9.2289 PubMedCrossRefGoogle Scholar

Copyright information

© US Government 2009

Authors and Affiliations

  • Sharon Saydah
    • 1
  • Rachel Ballard-Barbash
    • 2
  • Nancy Potischman
    • 2
  1. 1.Division of Diabetes TranslationCenter for Disease Control and PreventionHyattsvilleUSA
  2. 2.Applied Research Program, Division of Cancer Control & Population SciencesNational Cancer InstituteBethesdaUSA

Personalised recommendations